Integrative inflammasome activity in the regulation of intestinal mucosal immune responses

Mucosal Immunology

Volumn 6, Issue 1, 2013, Pages 4-13

  Elinav, E ^a,b   Henao Mejia, J ^a   Flavell, R A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AIM2 PROTEIN; CASPASE 11; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME; NLRC4 PROTEIN; NLRP1 PROTEIN; NLRP6 PROTEIN; UNCLASSIFIED DRUG;

CARCINOGENESIS; COLITIS; COLON CARCINOGENESIS; DISEASE ASSOCIATION; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE INFECTION; INTESTINE MUCOSA; MOLECULAR INTERACTION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84874028928     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2012.115     Document Type: Review

References (79)

1. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229-241 (2004). (Pubitemid 38962578)
2. Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278-286 (2012).
3. Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745-757 (2011).
4. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185 (2012).
5. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
6. Fernandes-Alnemri, T., Yu, J.W., Datta, P., Wu, J. & Alnemri, E.S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458, 509-513 (2009).
7. Kerur, N. et al. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. Cell Host Microbe. 9, 363-375 (2011).
8. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417-426 (2002). (Pubitemid 35007355)
9. Hornung, V. et al. AIM2 recognizes cytosolic dsDNA and forms a caspase- 1-activating inflammasome with ASC. Nature 458, 514-518 (2009).
10. Roberts, T.L. et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 323, 1057-1060 (2009).
11. Hsu, L.C. et al. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc. Natl. Acad. Sci. USA 105, 7803-7808 (2008).
12. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401-414 (2012).
13. Zhao, Y. et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477, 596-600 (2011).
14. Kofoed, E.M. & Vance, R.E. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477, 592-595 (2011).
15. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxininteracting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136-140 (2010).
16. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008).
17. Franchi, L. et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat. Immunol. 7, 576-582 (2006). (Pubitemid 43797338)
18. Lara-Tejero, M. et al. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J. Exp. Med. 203, 1407-1412 (2006). (Pubitemid 43877602)
19. Muller, A.J. et al. The S. Typhimurium effector SopE induces caspase-1 activation in stromal cells to initiate gut inflammation. Cell HostMicrobe. 6, 125-136 (2009).
20. Raupach, B., Peuschel, S.K., Monack, D.M. & Zychlinsky, A. Caspase-1- mediated activation of interleukin-1beta (IL-1beta) and IL-18 contributes to innate immune defenses against Salmonella enterica serovar Typhimurium infection. Infect. Immun. 74, 4922-4926 (2006). (Pubitemid 44157282)
21. Miao, E.A. et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol. 11, 1136-1142 (2010).
22. Sutterwala, F.S. et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24, 317-327 (2006).
23. Franchi, L., Munoz-Planillo, R. & Nunez, G. Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 13, 325-332 (2012).
24. Broz,P. et al. Redundant roles for inflammasome receptorsNLRP3andNLRC4 in host defense against Salmonella. J. Exp. Med. 207, 1745-1755 (2010).
25. Miao, E.A. et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc. Natl. Acad. Sci.USA 107, 3076-3080 (2010).
26. Suzuki, T. et al. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog. 3, e111 (2007).
27. Lightfield, K.L. et al. Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat. Immunol. 9, 1171-1178 (2008).
28. Lightfield, K.L. et al. Differential requirements for NAIP5 in activation of the NLRC4 inflammasome. Infect. Immun. 79, 1606-1614 (2011).
29. Liu, Z. et al. Role of inflammasomes in host defense against citrobacter rodentium infection. J. Biol. Chem. 287, 16955-16964 (2012).
30. Ayres, J.S., Trinidad, N.J. & Vance, R.E. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat. Med. 18, 799-806 (2012).
31. Franchi, L. et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13, 449-456 (2012).
32. Siegmund, B., Lehr, H.A., Fantuzzi, G. & Dinarello, C.A. IL-1 beta - converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. Sci. USA 98, 13249-13254 (2001). (Pubitemid 33051348)
33. Kayagaki, N. et al. Non-canonical inflammasome activation targets caspase-11. Nature 479, 117-121 (2011).
34. Loher, F. et al. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J. Pharmacol. Exp. Ther. 308, 583-590 (2004). (Pubitemid 38134220)
35. Bauer, C. et al. The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig. Dis. Sci. 52, 1642-1652 (2007). (Pubitemid 46870573)
36. Ishikura, T. et al. Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice. J. Gastroenterol. Hepatol. 18, 960-969 (2003). (Pubitemid 37056177)
37. Kanai, T. et al. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 121, 875-888 (2001). (Pubitemid 32959397)
38. Siegmund, B. et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1264-R1273 (2001).
39. Wirtz, S.,Becker,C., Blumberg,R., Galle, P.R.&Neurath,M.F. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J. Immunol. 168, 411-420 (2002). (Pubitemid 34014143)
40. Takagi, H. et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand. J. Gastroenterol. 38, 837-844 (2003). (Pubitemid 37011577)
41. Pizarro, T.T. et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 162, 6829-6835 (1999). (Pubitemid 29309411)
42. Kanai, T. et al. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterology 119, 1514-1523 (2000). (Pubitemid 32198677)
43. Takagawa, T. et al. Association between IL-18 gene promoter polymorphisms and inflammatory bowel disease in a Japanese population. Inflamm. Bowel Dis. 11, 1038-1043 (2005). (Pubitemid 41682559)
44. Tamura, K. et al. IL18 polymorphism is associated with an increased risk of Crohn's disease. J. Gastroenterol. 37 (Suppl 14), 111-116 (2002). (Pubitemid 35385941)
45. Zhernakova, A. et al. Genetic analysis of innate immunity inCrohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am. J. Hum. Genet. 82, 1202-1210 (2008).
46. Villani, A.C. et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet. 41, 71-76 (2009).
47. Lewis, G.J. et al. Genetic association between NLRP3 variants and Crohn's disease does not replicate in a large UK panel. Inflamm. Bowel Dis. 17, 1387-1391 (2011).
48. Dupaul-Chicoine, J. et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32, 367-378 (2010).
49. Zaki, M.H. et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32, 379-391 (2010).
50. Hirota, S.A. et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm. Bowel Dis. 17, 1359-1372 (2011).
51. Allen, I.C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045-1056 (2010).
52. Bauer, C. et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192-1199 (2010).
53. Siegmund, B. Interleukin-18 in intestinal inflammation: friend and foe?. Immunity 32, 300-302 (2010).
54. Chen, G.Y., Liu, M., Wang, F., Bertin, J. & Nunez, G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J. Immunol. 186, 7187-7194 (2011).
55. Normand, S. et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc. Natl. Acad. Sci. USA 108, 9601-9606 (2011).
56. Grenier, J.M. et al. Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1. FEBS Lett. 530, 73-78 (2002). (Pubitemid 35248189)
57. Henao-Mejia, J., Elinav, E., Strowig, T. & Flavell, R.A. Inflammasomes: far beyond inflammation. Nat. Immunol. 13, 321-324 (2012).
58. Bajaj, J.S. et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G168- G175 (2012).
59. Makiura, N. et al. Relationship of Porphyromonas gingivalis with glycemic level in patients with type 2 diabetes following periodontal treatment. Oral Microbiol. Immunol. 23, 348-351 (2008). (Pubitemid 351832173)
60. Rosenberg, D.W., Giardina, C. & Tanaka, T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 30, 183-196 (2009).
61. Rakoff-Nahoum, S. & Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317, 124-127 (2007). (Pubitemid 47056471)
62. Dove, W.F. et al. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res. 57, 812-814 (1997). (Pubitemid 27097999)
63. Lee, S.H. et al. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat. Med. 16, 665-670 (2010).
64. Jess, T., Rungoe, C. & Peyrin-Biroulet, L. Risk of colorectal cancer in patients with ulcerative colitis: ameta-analysis of population-based cohort studies. Clin. Gastroenterol. Hepatol. 10, 639-645 (2012).
65. Eaden, J.A., Abrams, K.R. & Mayberry, J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526-535 (2001). (Pubitemid 32234798)
66. Popivanova, B.K. et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118, 560-570 (2008). (Pubitemid 351206546)
67. Becker, C. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491-501 (2004). (Pubitemid 39370505)
68. Bollrath, J. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102 (2009).
69. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113 (2009).
70. Greten, F.R. et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296 (2004). (Pubitemid 39061110)
71. Salcedo, R. et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 207, 1625-1636 (2010).
72. Zaki, M.H., Vogel, P., Body-Malapel, M., Lamkanfi, M. & Kanneganti, T.D. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J. Immunol. 185, 4912-4920 (2010).
73. Chen, G.Y., Liu, M., Wang, F., Bertin, J. & Nunez, G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J. Immunol. 186, 7187-7194 (2011).
74. Normand, S. et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc. Natl. Acad. Sci. USA 108, 9601-9606 (2011).
75. Lich, J.D. et al. Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. J. Immunol. 178, 1256-1260 (2007). (Pubitemid 46154594)
76. Allen, I.C. et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity 36, 742-754 (2012).
77. Zaki, M.H. et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 20, 649-660 (2011).
78. Hu, B. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl. Acad. Sci. USA 107, 21635-21640 (2010).
79. Hu, B., Elinav, E. & Flavell, R.A. Inflammasome-mediated suppression of inflammation-induced colorectal cancer progression is mediated by direct regulation of epithelial cell proliferation. Cell Cycle 10, 1936-1939 (2011).